ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 462

Subcutaneous Abatacept: Long-Term Data From the Acquire Trial

M. C. Genovese1, C. Pacheco-Tena2, A. Covarrubias3, Gustavo Leon4, E. Mysler5, M. Keiserman6, R. Valente7, P. Nash8, J. A. Simon-Campos9, J. Box10, C. Legerton III11, E. Nasonov12, P. Durez13, I. Delaet14 and R. Alten15, 1Stanford University, Palo Alto, CA, 2Universidad Autónoma de Chihuahua, Chihuahua, Mexico, 3Centro Medico De Las Americas, Merida, Mexico, 4Instituto De Ginecologia Y Reproduccion, Lima, Peru, 5Organización Médica de Investigación, Buenos Aires, Argentina, 6Pontificial Catholic University School of Medicine, Porto Alegre, Brazil, 7Arthritis Center of Nebraska, Lincoln, NE, 8Rheumatology Research Unit, Nambour Hospital, Sunshine Coast and Department of Medicine, University of Queensland, Queensland, Australia, 9Centro De Especialidades Médicas/Universidad Marista, Merida, Mexico, 10Carolina Bone and Joint, Charlotte, NC, 11Low Country Rheumatology, Charleston, SC, 12Institute of Rheumatology, Moscow, Russia, 13Université Catholique de Louvain, Brussels, Belgium, 14Bristol-Myers Squibb, Princeton, NJ, 15Schlosspark-Klinik, University Medicine, Berlin, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Abatacept, clinical trials and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: The Abatacept (ABA) Comparison of Sub[QU]cutaneous (SC) versus Intravenous (IV) in Inadequate Responders to MethotrexatE (MTX) (ACQUIRE) study showed comparable efficacy and safety of SC vs IV ABA over 6 mths;1 here, we present 32-mth data from the long-term extension (LTE), during which all patients (pts) received SC ABA. Methods: ACQUIRE was a Phase IIIb, 6-mth, double-blind (DB) study of pts with active RA (³10 swollen and ³12 tender joint count [TJC and SJC], C-reactive protein (CRP) ≥0.8 mg/dL) refractory to MTX. Pts were randomized to SC ABA (125 mg/wk) with IV ABA loading (~10 mg/kg) on Day 1 or IV ABA (~10 mg/kg every 4 weeks) for 6 mths, plus MTX. After 6 mths, pts could enter the open-label LTE to receive SC ABA 125 mg/wk. Safety and efficacy were assessed for pts treated in the LTE, with efficacy presented according to original DB treatment group (as observed). Not all pts had reached later time points at time of analysis, as a result of differential enrollment in the trial. Results: Of 1372 pts entering the LTE, 1134 (82.7%) remained on therapy at time of reporting. Mean baseline RA duration was 8 yrs, TJC and SJC were 30 and 20, and HAQ-DI was 1.7. The median (range) ABA exposure was 33 (8–44) mths. The incidence rate (IR; events/100 pt-yrs) of serious adverse events for pts treated with SC ABA in the LTE (8.76 [95% CI: 7.71–9.95]) was comparable with that for SC ABA in the DB period (9.02 [6.31–12.90]) and did not increase with increasing exposure (not shown). The IR of overall and serious infections in the LTE (44.80 [41.81–48.01] and 1.72 [1.30–2.27], respectively) did not increase vs the DB period (84.62 [74.50–96.11] and 1.48 [0.62–3.56], respectively). Bacterial, viral and hospitalized infections occurred at IRs of 27.28 (25.16–29.57), 18.25 (16.61–20.06) and 1.55 (1.16–2.07) during the LTE. The IR of malignancy did not increase in the LTE (1.19 [0.86–1.66]) vs the DB period (0.59 [0.15–2.36]). Injection-site reactions occurred in 27 (2.0%) pts in the LTE (none serious) and 19 (2.6%) pts in the DB period. Overall, 139/1365 (10.2%) and 1/153 (0.7%) pts experienced immunogenicity (ECL) during the LTE and DB periods. ACR responses were maintained from Mth 6 to 32 and were comparable for original SC and IV groups (Figure). DAS28 (CRP) <2.6 rates (95% CIs) were 24 (21–27) [n=685] and 25% (22–28) [n=667] at Day 169 and 39 (33–44) [n=288] and 35% (29–40) [n=275] at Day 981 for the original SC and IV groups, respectively. HAQ-DI responses (change from baseline ≥0.3) were 73 (95% CI: 69–76) [n=691] and 68% (65–72) [n=672] at Day 169 and 74 (69–79) [n=313] and 70% (65–75) [n=303] at Day 981 for the original SC and IV groups, respectively. Conclusion: Over 32 months, SC abatacept showed consistent safety with high patient retention (82.7%). ACR, HAQ-DI responses and DAS28 remission rates were maintained through the long-term extension.  

1.    Genovese MC, et al. Arthritis Rheum 2011;63(10):2854–64   Figure.jpg


Disclosure:

M. C. Genovese,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5;

C. Pacheco-Tena,

BMS, Janssen, Roche and Pfizer,

5;

A. Covarrubias,
None;

G. Leon,
None;

E. Mysler,
None;

M. Keiserman,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5,

Bristol-Myers Squibb,

8;

R. Valente,

BMS, Novartis, Pfizer, UBS, Centocor, Lilly, Takada, HGS,

9;

P. Nash,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5,

Bristol-Myers Squibb,

8;

J. A. Simon-Campos,
None;

J. Box,

Clinical research for BMS,

2,

Bristol-Myers Squibb,

8;

C. Legerton III,

Bristol-Myers Squibb,

2;

E. Nasonov,
None;

P. Durez,

BMS – Less than US$2000 ,

8;

I. Delaet,

Bristol-Myers Squibb,

1,

Bristol-Myers Squibb,

3;

R. Alten,

ABBOTT, BMS, GSK,NOVARTIS, PFIZER, UCB,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/subcutaneous-abatacept-long-term-data-from-the-acquire-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology